OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER RECEIVING A CDK 4 AND 6 INHIBITOR plus FULVESTRANT AFTER PROGRESSING ON/AFTER PRIOR ENDOCRINE THERAPY: A FRACTIONAL POLYNOMIAL NETWORK META-ANALYSIS

被引：0
|
作者：
Hirst, A. [1 ]
Davie, A. [2 ]
Carter, Cuyun G. [3 ]
Haddad, N. [3 ]
Traore, S. [2 ]
Brufsky, A. [4 ]
Harbeck, N. [5 ]
Pivot, X. [6 ]
机构：
[1] ICON PLC, London, England
[2] Eli Lilly & Co Ltd, Windlesham, Surrey, England
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Univ Munchen LMU, Brustzentrum, Munich, Germany
[6] Paul Strauss Canc Ctr, Strasbourg, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN4
引用
收藏
页码：S421 / S421
页数：1
相关论文
共 50 条
  • [31] CDK4/6 inhibitors in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: An updated network meta-analysis and cost-effectiveness analysis
    Zeng, N.
    Han, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S369
  • [32] CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
    Zeng, Ni
    Han, Jiaqi
    Liu, Zijian
    He, Jinlan
    Tian, Kun
    Chen, Nianyong
    CANCERS, 2023, 15 (13)
  • [33] MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer
    Goetz, Matthew
    Toi, Masakazu
    Huober, Jens
    Sohn, Joo Hyuk
    Tredan, Olivier
    Park, Inhae
    Campone, Mario
    Chen, Shin-Cheh
    Manso, Luis Manual
    Paluch-Shimon, Shani
    Freedman, Orit C.
    Andre, Valerie
    Saha, Abhijoy
    van Hal, Gertjan
    Shahir, Ashwin
    Iwata, Hiroji
    Johnston, Stephen R. D.
    O'Shaughnessy, Joyce
    Pivot, Xavier
    Tolaney, Sara
    Hurvitz, Sara
    Llombart, Antonio
    CANCER RESEARCH, 2024, 84 (09)
  • [34] A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2-advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1)
    Hurvitz, Sara A.
    Andre, Fabrice
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    Giordano, Antonio
    Han, Hyo S.
    Martin, Miguel
    Pistilli, Barbara
    Rugo, Hope S.
    Wesolowski, Robert
    Suzuki, Samuel
    Mutka, Sarah C.
    Gorbatchevsky, Igor
    Loibl, Sibylle
    CANCER RESEARCH, 2023, 83 (08)
  • [35] Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2-advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials
    Yang, Lin
    Xue, Jingyi
    Yang, Zhengyu
    Wang, Meixue
    Yang, Ping
    Dong, Yanming
    He, Xianli
    Bao, Guoqiang
    Peng, Shujia
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (05) : 5590 - +
  • [36] A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2-advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1)
    Hurvitz, Sara A.
    Andre, Fabrice
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    Giordano, Antonio
    Han, Hyo S.
    Martin, Miguel
    Pistilli, Barbara
    Rugo, Hope S.
    Wesolowski, Robert
    Suzuki, Samuel
    Mutka, Sarah
    Gorbatchevsky, Igor
    Loibl, Sibylle
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2-metastatic breast cancer (MBC) after chemotherapy for advanced disease
    Cortes, J.
    Rugo, H. S.
    Tolaney, S. M.
    Dieras, V.
    Patt, D.
    Wildiers, H.
    Nanda, S.
    Koustenis, A.
    Dickler, M. N.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
    Jiayu Wang
    Qingyuan Zhang
    Huiping Li
    Zhongsheng Tong
    Quchang Ouyang
    Huihui Li
    Yuee Teng
    Biyun Wang
    Tao Sun
    Jingfen Wang
    Wei Li
    Zhaofeng Niu
    Hongsheng Li
    Chang Gong
    Shu Wang
    Xinshuai Wang
    Xinhong Wu
    Ning Liu
    Guohua Yu
    Fei Liu
    Xianghui Duan
    Shuya Wang
    Yaping Meng
    Li Wang
    Binghe Xu
    Nature Communications, 16 (1)
  • [39] Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
    Steger, Guenther G.
    Egle, Daniel
    Bartsch, Rupert
    Pfeiler, Georg
    Petru, Edgar
    Greil, Richard
    Helfgott, Ruth
    Marth, Christian
    Oehler, Leopold
    Hubalek, Michael
    Lang, Alois
    Tinchon, Christoph
    Haslbauer, Ferdinand
    Redl, Andreas
    Hock, Karin
    Hennebelle, Mathias
    Mraz, Bernhard
    Gnant, Michael
    BREAST, 2020, 50 : 64 - 70
  • [40] Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2,-3, and-7 studies of ribociclib plus endocrine therapy in patients with HR+/HER2-advanced breast cancer
    Carey, Lisa
    Solovieff, Nadia
    Andre, Fabrice
    O'Shaughnessy, Joyce
    Cameron, David A.
    Janni, Wolfgang
    Sonke, Gabe S.
    Yap, Yoon-Sim
    Yardley, Denise A.
    Zarate, Juan Pablo
    Taran, Tetiana
    Su, Faye
    Lteif, Agnes
    Prat, Aleix
    CANCER RESEARCH, 2022, 82 (04)
12345